Non-selective NSAID
Pregnancy: Avoid in third trimester (ductus arteriosus). Use for shortest time in second trimester only if essential.
Naproxen
Brand names: Naprosyn, Napratec, Naproxen EC
Adult dose
Dose: 250–500 mg twice daily; acute gout: 750 mg then 250 mg every 8 hours
Route: Oral
Frequency: Twice daily
Max: 1.25 g/day
RA/OA/AS: 500 mg BD. Acute gout: 750 mg initially then 250 mg every 8 hours until attack resolves (max 1.25 g/day). Acute musculoskeletal: 500 mg initially then 250 mg TDS. Always prescribe PPI (omeprazole 20 mg) with NSAID. Avoid in cardiovascular disease, renal impairment, elderly.
Paediatric dose
Dose: 5 mg/kg
Route: Oral
Frequency: Twice daily
Max: 500 mg/dose
≥5 years (JIA): 10 mg/kg/day in 2 divided doses (max 500 mg BD). Take with food or milk.
Dose adjustments
Renal
Avoid if eGFR <30. Use with caution eGFR 30–60. Risk of acute kidney injury.
Hepatic
Use with caution in mild-moderate hepatic impairment. Avoid in severe.
Paediatric weight-based calculator
≥5 years (JIA): 10 mg/kg/day in 2 divided doses (max 500 mg BD). Take with food or milk.
Clinical pearls
- Co-prescribe PPI (e.g., omeprazole 20 mg) for all patients taking NSAIDs regularly
- 'Triple whammy': NSAID + ACE inhibitor/ARB + diuretic — high AKI risk in elderly — avoid this combination
- Naproxen has better cardiovascular safety profile vs diclofenac and rofecoxib
- Use lowest effective dose for shortest duration in OA/RA
- Acute gout: faster onset than allopurinol — use for acute attacks while initiating ULT
Contraindications
- Active peptic ulcer / GI bleeding
- Severe heart failure
- Severe renal impairment (eGFR <30)
- Aspirin-exacerbated respiratory disease
- Pregnancy (third trimester — premature closure of ductus arteriosus)
Side effects
- GI upset, peptic ulceration, GI bleeding
- Fluid retention and oedema
- Hypertension (sodium retention)
- Renal impairment (acute or chronic)
- Hypersensitivity reactions
- Cardiovascular events (less than diclofenac; similar to ibuprofen)
Interactions
- Warfarin — increased bleeding risk (both GI and INR effects)
- Lithium — increases lithium levels
- Methotrexate — reduces MTX excretion (caution)
- Antihypertensives — reduced efficacy (NSAIDs raise BP)
- ACE inhibitors/ARBs — triple whammy with diuretics (AKI risk)
Monitoring
- U&E and creatinine (especially in elderly/renal risk)
- BP
- GI symptoms
- FBC (long-term)
Reference: BNFc; BNF; NICE NG100 RA; NICE NG219 Gout; MHRA NSAIDs prescribing guidance. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022